公司概述
BridgeBio Pharma, Inc. operates as a biopharmaceutical entity dedicated to the discovery, development, and delivery of therapeutic medicines specifically targeting patients suffering from genetic diseases. The company functions within the healthcare sector and the biotechnology industry, positioning itself to capitalize on the high-growth potential of specialized pharmaceutical research and genetic medicine advancements. Currently, BridgeBio holds a market capitalization of $14.64B, generates annual revenue of $502.08M, and maintains an employee base of 834 individuals. The substantial market cap relative to the annual revenue of approximately $502.08M suggests that the market places significant value on the company's pipeline assets and future commercial potential rather than current profitability. This valuation framework is typical for biotechnology firms where investor confidence is driven by the prospect of breakthrough therapies in genetic disease treatment rather than immediate earnings generation. The scale of operations involving 834 employees indicates a mature organizational structure capable of supporting extensive research and development initiatives required for bringing complex small molecule stabilizers to market.
财务健康
BridgeBio Pharma reported a trailing twelve-month revenue of $502.08M, yet posted a net income of -$724,931,008 and an EBITDA of -$496,630,016. The significant gap between the positive revenue of $502.08M and the negative net income of -$724,931,008 reveals a cost structure dominated by heavy research and development expenditures, general administrative costs, and clinical trial expenses that far exceed current sales proceeds. The company's free cash flow stands at -$325,290,624, which indicates that the firm is currently burning cash to fund its operations and pipeline progression rather than generating liquidity from its commercial activities. This negative cash flow position necessitates ongoing capital raising or the utilization of existing cash reserves to maintain solvency during the development phase. Analysis of the three primary margins shows a gross margin of 95.8%, reflecting the high value-added nature of pharmaceutical manufacturing where product costs are low relative to sales price. Conversely, the operating margin is -83.3% and the profit margin is -144.4%, indicating that operational inefficiencies and R&D outlays are severely impacting bottom-line profitability at this stage of the business lifecycle. On the liability side, the company holds $587.48M in cash against total debt of $1.86B, creating a net debt position that leverages the balance sheet. Although the debt-to-equity ratio is listed as N/A due to the absence of shareholder equity, the absolute debt load is more than three times the available cash, suggesting a leveraged balance sheet reliant on future financing. The current ratio is 2.77, which indicates that the company possesses sufficient current assets to cover its short-term liabilities nearly three times over, providing a buffer for immediate liquidity needs despite the overall negative cash flow. Return on Equity is N/A because there is no positive equity base to measure against, while Return on Assets is -33.8%, revealing that for every dollar of assets employed, the company loses approximately 34 cents in value annually.
估值评估
BridgeBio Pharma does not have a trailing P/E ratio available as earnings are negative, but the forward P/E is listed at 37760.00. The discrepancy between the non-existent trailing P/E and the astronomical forward P/E implies that the market is pricing in significant expected earnings growth in the future that is not yet realized in historical financial statements. The price-to-book ratio is -7.05, which indicates that the company's market capitalization is negative relative to its book value, a common characteristic of biotechnology firms with substantial intangible assets and negative net book value due to accumulated R&D costs. The price-to-sales ratio stands at 29.16, and the EV/EBITDA is -32.07, suggesting that valuation is driven almost entirely by sales potential and asset exclusivity rather than earnings multiples or enterprise value efficiency. The stock's trading range over the last year spans from a low of $28.32 to a high of $84.94, meaning the current price sits within this historical band where extreme volatility is observed. The beta value of 1.09 indicates that the stock's price volatility is slightly higher than the broader market, moving 9% more than the market index on average during periods of fluctuation. These metrics collectively paint a picture of a high-risk, high-reward valuation profile typical of pre-revenue or late-stage clinical biotechnology companies.
Growth & Income
BridgeBio Pharma has achieved a revenue growth rate of 2521.2% year-over-year, while earnings growth is N/A due to the company's continued losses. Since earnings are negative, they are not growing faster than revenue; rather, the massive revenue expansion is being consumed by escalating costs, preventing profitability from materializing. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. The absence of a dividend payout is a standard characteristic for biotechnology firms at this stage, as the 0.0% payout ratio reflects a strategy of retaining all available cash to reinvest into research and development rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined by aggressive top-line expansion funded by capital markets, with no current income generation for investors. The company's financial model prioritizes asset development and clinical trial completion over immediate shareholder returns, which aligns with the industry standard for genetic disease therapeutics in the early to mid-development phases.